Literature DB >> 11362021

Models of viral kinetics and drug resistance in HIV-1 infection.

S Bonhoeffer1.   

Abstract

Mathematical models have become an increasingly valuable tool in HIV research. In particular, the mathematical analysis of drug-induced perturbations of the steady-state viral load in chronically infected patients has led to fundamental new insights into HIV dynamics in vivo and demonstrated that there is highly active viral replication throughout the course of infection. The same models can be used to address issues related to drug resistance and may eventually provide theoretical guidelines for the design of efficient treatment strategies. The goal of this article is to illustrate to a readership with nonmathematical background how these models work, what key assumptions they make, and which questions they may help to answer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 11362021     DOI: 10.1089/apc.1998.12.769

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  5 in total

1.  Production of resistant HIV mutants during antiretroviral therapy.

Authors:  R M Ribeiro; S Bonhoeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.

Authors:  Philippe Jacqmin; Lynn McFadyen; Janet R Wade
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

3.  Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling.

Authors:  Philippe Jacqmin; Lynn McFadyen; Janet R Wade
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-03-04       Impact factor: 2.745

4.  Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.

Authors:  Daniel Röshammar; Ulrika S H Simonsson; Håkan Ekvall; Leo Flamholc; Vidar Ormaasen; Jan Vesterbacka; Eva Wallmark; Michael Ashton; Magnus Gisslén
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-02       Impact factor: 2.745

5.  A Mechanistic In Vivo/Ex Vivo Pharmacokinetic-Pharmacodynamic Model of Tenofovir for HIV Prevention.

Authors:  Priya Jayachandran; Maria Garcia-Cremades; Katarina Vučićević; Namandjé N Bumpus; Peter Anton; Craig Hendrix; Radojka Savić
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-02-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.